venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q4 2019 (← Previous) (Next →)

Filing Date: May 20, 2020

Total Value ($000): $233,252 (100.0% shares, 0.0% debt)

Holdings (6)

— AKERO THERAPEUTICS INC 37.5%

Value ($000) $87,460 Shares 3,940,543 Est. Cost $19.15 Unrealized —

— PRECISION BIOSCIENCES INC 25.4%

Value ($000) $59,243 Shares 4,265,141 Est. Cost $17.95 Unrealized —

— TURNING POINT THERAPEUTICS I 18.9%

Value ($000) $44,116 Shares 708,233 Est. Cost $40.70 Unrealized —

APLS APELLIS PHARMACEUTICALS INC 13.1%

Value ($000) $30,620 Shares 1,000,000 Est. Cost $15.34 Unrealized +80.4%

— MENLO THERAPEUTICS INC 2.9%

Value ($000) $6,782 Shares 1,461,552 Est. Cost $4.12 Unrealized —

— VERONA PHARMA PLC 2.2%

Value ($000) $5,031 Shares 875,000 Est. Cost $9.65 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	AKERO THERAPEUTICS INC	3,940,543	$87,460	37.5%	$19.15	—	COM	00973Y108
—	PRECISION BIOSCIENCES INC	4,265,141	$59,243	25.4%	$17.95	—	COM	74019P108
—	TURNING POINT THERAPEUTICS I	708,233	$44,116	18.9%	$40.70	—	COM	90041T108
APLS	APELLIS PHARMACEUTICALS INC	1,000,000	$30,620	13.1%	$15.34	+80.4%	COM	03753U106
—	MENLO THERAPEUTICS INC	1,461,552	$6,782	2.9%	$4.12	—	COM	586858102
—	VERONA PHARMA PLC	875,000	$5,031	2.2%	$9.65	—	SPONSORED ADS	925050106